Ownership Submission
FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Heft Robert
2. Date of Event Requiring Statement (Month/Day/Year)
12/19/2017
3. Issuer Name and Ticker or Trading Symbol
Eloxx Pharmaceuticals, Inc. [SVOND]
(Last)
(First)
(Middle)
C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER STREET, 4TH FLOOR NORTH
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

WALTHAM, MA 02451
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   (1) 12/14/2024 Common Stock 291,499 (3) $ 0.96 (3) D  
Stock Option (Right to Buy)   (2) 12/14/2026 Common Stock 48,916 (3) $ 1 (3) D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Heft Robert
C/O ELOXX PHARMACEUTICALS, INC.
950 WINTER STREET, 4TH FLOOR NORTH
WALTHAM, MA 02451
  X      

Signatures

/s/ Gregory Weaver, Attorney in Fact 12/29/2017
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The option vested over a three-year period commencing on January 24, 2014 in twelve equal quarterly installments and became fully vested and exercisable as of January 24, 2017.
(2) The option vests over a three-year period commencing on January 24, 2016 in twelve equal quarterly installments.
(3) Exercise price and number of option shares, as applicable, have been adjusted to reflect the Issuer's 1-for-20 reverse stock split of its issued and outstanding shares of common stock effected on December 19, 2017.
 
Remarks:
Exhibit 24 - Power of Attorney. Gregory Weaver, Chief Financial Officer, is signing on behalf of Dr. Robert Heft pursuant to a Power of Attorney dated December 16, 2017, which is attached hereto as an exhibit.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.